German market leader within a few years

Business development

M1 has a clear growth strategy within the established business model. Since the opening of our first location in Berlin in 2012, we have continuously developed. Today, M1 is the market leader in Germany and has started the international expansion. In the coming years we will open numerous new locations in Germany and roll out the successful their model internationally. We see great potential in practically every country in Western Europe and beyond. After all, the markets for cosmetic surgery are very fragmented and prices are too high.

In addition, we see potential in other areas of aesthetic and plastic medicine and, from a medical point of view, the demand for specialization. That, we want to take advantage of.


Latest news

| Investor News

  • Group revenue: increase by 7% to EUR 339.2 million (previous year: EUR 316.3 million)
  • EBITDA: increase by 52% to EUR 32.0 million (previous year: EUR 21.0 million)
  • EBIT: increase by 70% to EUR 26.8 million (previous year: EUR 15.7 million)
  • EBT: increase by 60% to EUR 26.3 million (previous year: EUR 16.4 million)
  • Earnings per share: increase of 57% to EUR 0.85 (previous year: EUR 0.54)
  • Equity ratio: increase from 67% to 71%

| Ad-hoc news

HAEMATO AG, which is majority-owned by M1 Kliniken AG, has received a so-called Conditional Binding Offer (CBO) for the acquisition of its trading segment, the wholly-owned subsidiary HAEMATO PHARM GmbH. The Executive Board and Supervisory Board of HAEMATO AG are currently carefully reviewing the offer.

A possible sale of the trade segment would pave the way for a clear strategic focus of M1 Kliniken AG on the fast-growing beauty business.

The company will provide further information in due course.

| Investor News

  • Group: sales +8.7% to EUR 257.22 million and EBIT +70.7% to EUR 22.09 million
  • Beauty segment growth driver with sales +33.5% to EUR 71.02 million
  • EBIT in the Beauty segment +30.4% to EUR 16.26 million
  • Medium-term target confirmed: World's leading private provider of beauty treatments

| Investor News

  • Group: sales +11.2% to EUR 167.7 million and EBIT +98.8% to EUR 14.5 million
  • Earnings per share increased from EUR 0.17 to EUR 0.53
  • Beauty segment: sales +30.6% and EBIT +24.3%
  • Profitable growth to be continued